

DAFTAR PUSTAKA

1. Pradjatmo H. Upaya Meningkatkan Kelangsungan Hidup (survival) Penderita Kanker Ovarium : Masalah dan Tantangan. Yogyakarta:Universitas Gadjah Mada; 2018 (Diakses Agustus 2019). Tersedia dari : https://repository.ugm.ac.id/274713/1/heru_pradjatmo_opt.pdf.
2. Jordan SJ. Epidemiology of Epithelial Ovarian Cancer. Elsevier. 2017;41:3-14.
3. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian Cancer Statistics, 2018. CA Cancer J Clin. 2018;68(4):284-296.
4. WHO. Indonesia Global Cancer Observatory. International Agency for Research on Cancer. 2018 (Diakses Oktober 2019). Tersedia dari : https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia_factsheets.pdf.
5. Rambe IR, Asri A, Adrial A. Profil Tumor Ganas Ovarium di Laboratorium Patologi Anatomi Fakultas Kedokteran Universitas Andalas Periode Januari 2011 Sampai Desember 2012. Jurnal Kesehatan Andalas. 2014;3(1).
6. Koshiyama M, Matsumura N, Konishi I. Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. BioMed Research International. 2014.
7. Rauh-Hain JA, Krivak TC, Carmen MG, Olawaiye AB. Ovarian Cancer Screening and Early Detection in the General Population. Reviews in Obstetrics & Gynecology. 2011;4(1).
8. Chang LC, Huang CF, Lai M-S, Shen LJ, Wu F-LL, et al. Prognostic factors in epithelial ovarian cancer: A population-based study. PLoS ONE 13(3): e0194993.
9. Suastari NMP. Pemeriksaan Radiologi untuk Deteksi Kanker Ovarium. Denpasar: Fakultas Kedokteran Universitas Udayana; 2018;45(4).
10. WebMD. What Are the Symptoms of Ovarian Cancer?. 2019 (Diakses September 2019). Tersedia dari : <https://www.webmd.com/ovarian-cancer/what-are-ovarian-cancer-symptoms>.
11. Rujuta J, Nandita M. Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass. The Journal of Obstetrics and Gynecology of India. 2015; 65(2):117–121.

12. Putri IA. Perbandingan Rata Rata Skor RMI pada Kanker Epitel Ovarium Stadium Awal dengan Stadium Lanjut. Padang : Fakultas Kedokteran Universitas Andalas (Skripsi);2017.
13. Snell RS. Anatomi Klinis Berdasarkan Sistem. 2006.
14. Junqueira. Basic Histology Text and Atlas 14th Edition. 2007.
15. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian Cancer in the World: Epidemiology and Risk Factors. *International Journal of Women's Health*. 2019;11:287–299.
16. Mundhofir FEP, Wulandari CE, Prajoko YW, Winarni TI. BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia. *Asian Pac J Cancer Prev*. 2016;17(3):1539-1546.
17. Zahari A, Sudiyatmo. Hereditary Non-Polyposis Colorectal Cancer (lynch syndrome) pada Wanita Umur 16 Tahun. *Majalah kedokteran andalas*. Juli-Des 2011; 35(2).
18. Strauss JF, Alvarez RD, Bowen DJ, Cho KR, Donovan H, Duquette D, et al. Ovarian cancers: Evolving paradigms in research and care. Washington, DC: The National Academies Press. 2016:32.
19. Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R, et al. Epithelial Ovarian Cancer: An overview. *World J Transl Med*. 2014;3(1):1–8.
20. Fathalla MF. Incessant Ovulation and Ovarian Cancer. *Facts Views Vis Obgyn*. 2013; 5(4): 292–297.
21. Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and Ovarian Cancer. *Endocrine Reviews*. 2007; 28(4):440 – 461.
22. Perri F , Pisconti S , Scarpati GDV. P53 Mutations and Cancer: A Tight Linkage. *Ann Transl Med*. 2016;4(24):522.
23. Rasmussen CB, Kjaer SK, Albieri V, Bandera EV, Doherty JA. Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies. *Am J Epidemiol*. 2017; 185(1): 8–20.
24. Savant SS, Sriramkumar S, O'Hagan HM. The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. *Cancers (Basel)*. 2018;10(8).

25. Shisheboran MD, Genestie C. Pathobiology of Ovarian Carcinomas. *Chinese Journal of Cancer* . 2015;34(1):50-55.
26. Smith ER, Xu XX. Ovarian Ageing, Follicle Depletion, and Cancer: A Hypothesis for the Aetiology of Epithelial Ovarian Cancer Involving Follicle Depletion. *Lancet Oncol*. 2008; 9(11): 1108–1111.
27. Cramer DW. Determinants of Ovarian Cancer Risk. II. Inferences Regarding Pathogenesis. *J Natl Cancer Inst*. 1983 Oct;71(4):717-21.
28. Ehdavand S. WHO Classification of Ovarian Neoplasms. *PathologyOutlines.com*. 2019 (Diakses Oktober 2019). Tersedia dari : <https://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html>.
29. Chen VW, Ruiz B, Killeen JL, Cote TR, Wu XC, Correa CN, et al. Pathology and Classification of Ovarian Tumors. *Cancer supplement*. 2003;97(15).
30. Doubeni CA, Doubeni ARB, Myers AE. Diagnosis and Management of Ovarian Cancer. *American Family Physician*. 2016;93(11).
31. Krivak TC. Cytoreductive Surgery Goals in Advanced Ovarian Cancer. 2019 (Diakses pada Oktober 2019). Tersedia dari : <https://www.targetedonc.com/case-based-peer-perspectives/gynecologic-cancer/krivak-advanced-ovarian-cancer/cytoreductive-surgery-goals-in-advanced-ovarian-cancer>.
32. Berek JS, Kehoe ST, Kumar L, Friedlander M. Cancer of the Ovary, Fallopian Tube, and Peritoneum. *Int J Gynecol Obstet*. 2018;143 (Suppl. 2):59–78.
33. Camean MM, Sanchez ED, Pinera A, Diestro MD, Santiago JD, Zapardial I. The Role of Surgery in Advanced Epithelial Ovarian Cancer. *Ecancermedalscience*. 2016;10: 666.
34. Gibbs R, Karlan B, Haney AF, Nygaard IE. *Danforth's Obstetrics and Gynecology Tenth Edition*. Lippincott William & Wilkins. 2008;61:1022-60.
35. Pemaron R. Perbedaan Kadar Cancer Antigen-125 dan Human Epididimis-4 pada Kanker Ovarium Tipe Epitelial Stadium I, Stadium II dan Stadium III. RSUP sanglah Denpasar (Thesis); 2016.
36. Budiana ING. Tumor Ovarium : Prediksi Keganasan Prabedah. *Medicina*. 2013;44(3).
37. Gupta D, Lis CG. Role of CA125 in Predicting Ovarian Cancer Survival - A Review of the Epidemiological Literature. *Journal of Ovarian Research*. 2009;2(13).

38. Abdulrahman GO, McKnight L, Singh KL. The Risk of Malignancy Index (RMI) in Women with Adnexal Masses in Wales. *Taiwanese Journal of Obstetrics & Gynecology*. 2014;53:376-381.
39. Akturk E, Karaca RE, Alanbay I, Dede M, Karasahin E, Yenen MC, et al. Comparison of Four Malignancy Risk Indices in the Detection of Malignant Ovarian Masses. *Journal of Gynecologic Oncology*. 2011;22(3):177-182.
40. Suryantara. Perbandingan Risk of Malignancy Index (RMI) 4 dan 3 Sebagai Uji Diagnostik Keganasan Tumor Ovarium. Yogyakarta : Universitas Gadjah Mada (Thesis) ; 2012.
41. Dora SK, Dandapat AB, Pande B, Hota JP. A Prospective Study to Evaluate the Risk Malignancy Index and its Diagnostic Implication in Patients with Suspected Ovarian Mass. *Journal of Ovarian Research* ; 2017.
42. Putri FH. Hubungan Kadar CA-125 dengan Gambaran Histopatologi Pasien Kanker Ovarium Epitelial di RSUD DR. M Djamil. Padang : Fakultas Kedokteran Universitas Andalas (Skripsi) ; 2019.
43. Rima K. Tumor Ganas Ovarium di Bagian Patologi Anatomi Fakultas Kedokteran Universitas Andalas Padang. Universitas Andalas Padang (Skripsi) ; 2006.
44. Arania R. Karakteristik Pasien Kanker Ovarium di Rumah Sakit Dr. H. Abdul Moeloek Bandar Lampung Tahun 2009-2013 . *JuKe Unila*. 2015;5:9.
45. Wijaya R, Murti K, Hafy Z. Hubungan Kadar CA-125 dengan Subtipe Epitel Tumor Ganas Ovarium pada Penderita yang Dirawat di RSUD Dr. Mohammad Hoesin Palembang Tahun 2013-2016. *Majalah Kedokteran Sriwijaya*, Th. 49. 2017;4.
46. Johari AB, Siregar FG. Insidensi Kanker Ovarium Berdasarkan Faktor Risiko di RSUD Haji Adam Malik tahun 2008-2011. *E-Jurnal FK USU*. 2013;1(1):1-6.
47. Simamora RPA, Hanriko R, Sari RDP. Hubungan Usia, Jumlah Paritas, dan Usia Menarche terhadap Derajat Histopatologi Kanker Ovarium di RSUD Dr. H. Abdul Moeloek Bandar Lampung Tahun 2015-2016. *Majority*. 2018;7(2).
48. Moore, R.G. McMeekin, D.S. Brown, A.K. 2009. A Novel Multiple Marker Bioassay Utilizing HE4 and CA125 for the Prediction of Ovarian Cancer in Patients with a Pelvic Mass. *Gynecologic Oncology* 112: 40-46.

49. Meray O, Türkçüoğlu I, Meydanlı MM, Kafkaslı A. Risk of Malignancy Index is Not Sensitive in Detecting Nonepithelial Ovarian Cancer and Borderline Ovarian Tumor. *J Turkish-German Gynecol Assoc.* 2010;11:22-6.
50. Kurman RJ, Shih Ie M. Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer-Shifting the Paradigm. *Hum Pathol.* 2011;42:918-931.
51. Maryani D, Adisasmita AC, Dwipoyono B. Hubungan Riwayat Reproduksi, Penggunaan Hormon, dan Riwayat Kanker pada Keluarga dengan Kanker Ovarium pada Pasien RS Kanker Dharmais Jakarta Tahun 2013 : Fakultas Kesehatan Masyarakat Universitas Indonesia ; 2013.
52. Momenimovahed Z, Tiznobaik A, Taheri S, et al. Ovarian Cancer in the World : Epidemiology and Risk Factors. 201;11:287-299.
53. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women. *Am J Epidemiol.* 2008; 167(9): 1059–1069.
54. Ferdiansyah T, Sofian A, Fatmawati. Hubungan Tumor Marker CA-125 dengan Sifat dan Tipe Sel Tumor Ovarium di RSUD Arifin Achmad Pekanbaru : Fakultas Kedokteran Universitas Riau ; 2014.
55. Tiwari RK, Kaushik S, Debasis M, Chhanda D, Uttara C, Kumar GT. Evaluation of Preoperative Serum Levels of CA 125 and Expression of p53 in Ovarian Neoplasms: A Prospective Clinicopathological Study in Tertiary Care Hospital. *The J Obst Gyn India.* 2016;66(2):107-14.
56. Xu X, Wang Y, Wang F, Jia L, Zhou Y, Deng F, et al. Nadir CA-125 Level as Prognosis Indicator of High-Grade Serous Ovarian Cancer. *J Ovarian Res.* 2013;1:6-31.
57. Kolwicz E, Thomas CMG, Bulten J, Massuger LF. Preoperative CA-125 Levels in 123 Patients with Borderline Ovarian Tumors. *Int J Gyn Cancer.* November 2009;19(8):1335-8.
58. Kurman RJ, Shih IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. *Am J Pathol.* 2016;186:733-747.
59. Cancer Genome Atlas Research Network. Integrated Genomic Analyses of Ovarian Carcinoma. *Nature.* 2011;474:609–615.
60. Patch, AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, et al. Whole-Genome Characterization of Chemoresistant Ovarian Cancer. *Nature.* 2015;521:489–494.

61. Vang R, Shih LM, Kurman RJ. Ovarian Low-Grade and High-Grade Serous Carcinoms: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems. *Adv Anat Pathol.* 2009;16(5):267–282.
62. Ariningtyas ND. CA 125 dan Pemakaian Klinis dalam Penatalaksanaan Kanker Ovarium. *Qanun Medika.* 2018; 2(2).
63. Kalpna M, Kanchanmala G. Childhood Ovarian Malignancy. *The Journal of Obstetrics and Gynecology of India.* 2014; 64(2):91–94.
64. Ricci F, Affatato R, Carrassa L, Damia G. Recent Insights into Mucinous Ovarian Carcinoma. *Int. J. Mol. Sci.* 2018;19:1569.
65. Gorp TV, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the Development of Malignant Tumours of the Pelvis. A Review of Literature, Best Practice and Research: Clinical Obstetrics and Gynaecology. 2014; 18(2):349–371.
66. McCluggage WG. Morphological Subtypes of Ovarian Carcinoma: A Review with Emphasis on New Developments and Pathogenesis. *Pathology.* 2011;43: 420–32.
67. Prat J. Ovarian Carcinomas: Five Distinct Diseases with Different Origins, Genetic Alterations, and Clinicopathological Features. *Virchows Arch.* 2012; 460:237–49.
68. Reid BM, Permuth JB, Sellers TA. Epidemiology of Ovarian Cancer: A Review. *Cancer Biol Med.* 2017.
69. Wu R, Baker SJ, Cho KR. Type I to Type II Ovarian Carcinoma Progression. *The American Journal of Pathology.* 2013;182(4):1391-1399.

